Tudor Investment Corp ET AL Has $2.74 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)

Tudor Investment Corp ET AL reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 35.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 82,127 shares of the biotechnology company’s stock after selling 44,709 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Exelixis were worth $2,735,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Susquehanna Fundamental Investments LLC bought a new position in Exelixis in the 4th quarter worth approximately $12,055,000. Kovitz Investment Group Partners LLC boosted its position in shares of Exelixis by 10.8% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 19,653 shares of the biotechnology company’s stock valued at $654,000 after acquiring an additional 1,914 shares during the period. Hancock Whitney Corp grew its stake in shares of Exelixis by 1.6% in the fourth quarter. Hancock Whitney Corp now owns 48,473 shares of the biotechnology company’s stock worth $1,614,000 after acquiring an additional 740 shares during the last quarter. Syon Capital LLC bought a new position in Exelixis during the fourth quarter worth $313,000. Finally, Coppell Advisory Solutions LLC acquired a new position in Exelixis during the 4th quarter valued at $25,000. 85.27% of the stock is currently owned by institutional investors.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares in the company, valued at $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the transaction, the director now owns 33,514 shares in the company, valued at approximately $1,248,396.50. The trade was a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock valued at $5,177,234 over the last quarter. Corporate insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

EXEL has been the topic of several research reports. Barclays boosted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. UBS Group reaffirmed an “underperform” rating on shares of Exelixis in a report on Thursday, April 17th. Guggenheim reissued a “buy” rating and set a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Citigroup upped their target price on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Stock Performance

Exelixis stock opened at $39.60 on Friday. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The firm has a market cap of $10.91 billion, a P/E ratio of 22.37, a P/E/G ratio of 1.13 and a beta of 0.57. The business’s fifty day moving average is $36.95 and its two-hundred day moving average is $35.04.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.